| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 05/23/2001 | EP1100909A2 Dna replication- and repair-associated proteins |
| 05/23/2001 | EP1100907A2 Human cytoskeletal proteins |
| 05/23/2001 | EP1100894A2 Short oligonucleotides for the inhibition of vegf expression |
| 05/23/2001 | EP1100887A1 Growth differentiation factor-11 |
| 05/23/2001 | EP1100882A1 Human protein kinase h2lau20 |
| 05/23/2001 | EP1100822A1 Secreted cysteine rich protein-6 (scrp-6) |
| 05/23/2001 | EP1100813A1 HUMAN BOMBESIN RECEPTOR SUBTYPE-3sb |
| 05/23/2001 | EP1100808A1 Prostate derived ets factor |
| 05/23/2001 | EP1100794A1 COMPOUNDS SPECIFIC FOR THE HUMAN $g(a) 1d? ADRENERGIC RECEPTOR AND USES THEREOF |
| 05/23/2001 | EP1100792A1 Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases |
| 05/23/2001 | EP1100542A2 Peg-urate oxidase conjugates and use thereof |
| 05/23/2001 | EP1100524A2 Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions |
| 05/23/2001 | EP1100519A1 Multibinding agents that modulate nmda receptors |
| 05/23/2001 | EP1100503A2 Non-imidazole alkylamines as histamine h 3?-receptor ligands and their therapeutic applications |
| 05/23/2001 | EP1100486A1 Macrophage scavenger receptor antagonists |
| 05/23/2001 | EP1100484A1 Macrophage scavenger receptor antagonists |
| 05/23/2001 | EP1100476A1 Formulations for the transdermal administration of fenoldopam |
| 05/23/2001 | EP0750614B1 Quinazolinyl-amino derivatives having alpha-antagonist activity |
| 05/23/2001 | CN1296485A Substituted indolealkanoic acids |
| 05/23/2001 | CN1295842A Shenxian kidney-invigrating extract |
| 05/23/2001 | CN1066142C 喹唑啉衍生物 Quinazoline derivatives |
| 05/22/2001 | US6235970 CICM cells and non-human mammalian embryos prepared by nuclear transfer of a proliferating differentiated cell or its nucleus |
| 05/22/2001 | US6235969 Cloning pigs using donor nuclei from non-quiescent differentiated cells |
| 05/22/2001 | US6235877 Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors |
| 05/22/2001 | US6235764 Isothiazole derivatives useful as anticancer agents |
| 05/22/2001 | US6235750 Nitric oxide synthase inhibitor |
| 05/22/2001 | US6235742 5-substituted pyrazolo[4,3-D]pyrimidin-7-ones |
| 05/22/2001 | US6235735 Aftertreatment of radiation therapy |
| 05/22/2001 | US6235717 Pharmaceutical compounds |
| 05/17/2001 | WO2001034805A2 Human vanilloid receptor gene |
| 05/17/2001 | WO2001034800A1 19 human secreted proteins |
| 05/17/2001 | WO2001034768A2 15 human secreted proteins |
| 05/17/2001 | WO2001034767A2 22 human secreted proteins |
| 05/17/2001 | WO2001034643A1 24 human secreted proteins |
| 05/17/2001 | WO2001034628A1 35 human secreted proteins |
| 05/17/2001 | WO2001034627A1 28 human secreted proteins |
| 05/17/2001 | WO2001034623A1 29 human secreted proteins |
| 05/17/2001 | WO2001034614A2 Compositions and methods for double-targeting virus infections and targeting cancer cells |
| 05/17/2001 | WO2001034610A1 Polycycloalkylpurines as adenosine receptor antagonists |
| 05/17/2001 | WO2001034607A1 Pdgf receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same |
| 05/17/2001 | WO2001034604A2 Adenosine receptor antagonists and methods of making and using the same |
| 05/17/2001 | WO2001034594A1 Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors |
| 05/17/2001 | WO2001034593A1 Compound with growth hormone releasing properties |
| 05/17/2001 | WO2001034562A1 Aralkyl-1,2-diamines having calcimimetic activity and preparation mode |
| 05/17/2001 | WO2001034176A1 A method and composition for treating prostate cancer |
| 05/17/2001 | WO2001034147A1 Oral solid preparation |
| 05/17/2001 | WO2001034141A1 Il-8 receptor antagonists |
| 05/17/2001 | WO2001034139A1 Pharmaceutical formulation containing tolterodine and its use |
| 05/17/2001 | WO2001012598A9 METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF |
| 05/17/2001 | WO2001007471A9 Cell cycle and proliferation proteins |
| 05/17/2001 | WO2001001973A8 Highly selective norepinephrine reuptake inhibitors and methods of using the same |
| 05/17/2001 | WO2000049137B1 Pluripotential cell derived from an embryonic stem cell and a nucleus of a somatic cell |
| 05/17/2001 | WO2000040613A9 Insulin-like growth factor (igf) i mutant variants |
| 05/17/2001 | US20010001310 Bispecific antibodies for retargeting anticancer cytotoxic lymphocytes |
| 05/17/2001 | US20010001309 For treating pathologies related to altered alpha v beta 3 integrin-mediated cell attachment, in particular wherein inhibition of angiogenesis is desired, for example in tumors, also associated with metastasis |
| 05/17/2001 | CA2428827A1 Human vanilloid receptor gene |
| 05/17/2001 | CA2390880A1 Aralkyl-1,2-diamines having calcimimetic activity and preparation mode |
| 05/17/2001 | CA2390496A1 Polycycloalkylpurines as adenosine receptor antagonists |
| 05/17/2001 | CA2390438A1 19 human secreted proteins |
| 05/17/2001 | CA2390421A1 24 human secreted proteins |
| 05/17/2001 | CA2390231A1 Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors |
| 05/17/2001 | CA2389724A1 28 human secreted proteins |
| 05/17/2001 | CA2389722A1 15 human secreted proteins |
| 05/17/2001 | CA2389326A1 35 human secreted proteins |
| 05/17/2001 | CA2389176A1 A method and composition for treating prostate cancer |
| 05/17/2001 | CA2388008A1 29 human secreted proteins |
| 05/17/2001 | CA2387964A1 22 human secreted proteins |
| 05/17/2001 | CA2387624A1 Pdgf receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same |
| 05/17/2001 | CA2359955A1 Human vanilloid receptor gene |
| 05/16/2001 | EP1098906A1 Peptide analogues of pacap |
| 05/16/2001 | EP1098884A1 Il-8 receptor antagonists |
| 05/16/2001 | EP1098634A2 Bioenhanced formulations comprising eprosartan in oral solid dosage form |
| 05/16/2001 | CN1295579A Therapeutic uses of keratinocyte growth factor-2 |
| 05/16/2001 | CN1295563A 2-arylethyl-(piperidin-4-ylmethyl) amine derivatives as muscarinic receptor antagonists |
| 05/16/2001 | CN1295479A Beta 2-adrenergic receptor agonist |
| 05/16/2001 | CN1065861C Phenyl substituted alkenocarboxylic guanidine, preparation method application as medicine or diagnostic agent and medicine containing it |
| 05/16/2001 | CN1065757C Application of theachrome in preparing medicine for hyperuricemia |
| 05/16/2001 | CN1065756C Application of theachrome in preparing medicine for prostatauxe |
| 05/15/2001 | US6232452 Autosomal dominant disorder of growths in many tissues and organs identified on chromosome 16 deletion mutations; use in disease diagnosis and screening; the gene may behave as a tumor suppressor |
| 05/15/2001 | US6232321 Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| 05/15/2001 | US6232315 Method for treating inflammatory diseases by administering a thrombin inhibitor |
| 05/15/2001 | US6232307 2-phenyl-1-(4-(2-aminoethoxy)-benzyl)-indole compounds useful as estrogenic agents |
| 05/15/2001 | US6232305 Substituted amino bicyclic-β-lactam penam and cepham derivatives as cysteine protease inhibitors |
| 05/15/2001 | US6232289 Method of treating interstitial cytitis with recombinant heparin-binding epidermal growth factor-like growth factor (HB-EGF) |
| 05/15/2001 | US6232064 Fibrosis and atherosclerosis determination |
| 05/15/2001 | CA2180011C Botulinum toxins for treating sweating |
| 05/10/2001 | WO2001033221A1 Axor35, a g-protein coupled receptor |
| 05/10/2001 | WO2001032925A1 Modulation of neuroendocrine differentiation by protein 25.1 |
| 05/10/2001 | WO2001032888A2 Human transferase molecules |
| 05/10/2001 | WO2001032878A2 A novel polypeptide hormone phosphatonin |
| 05/10/2001 | WO2001032865A1 Human gpr27-like g-protein coupled receptor polypeptide and polynucleotide sequences |
| 05/10/2001 | WO2001032705A1 Ghsr ligand polypeptides and dnas thereof |
| 05/10/2001 | WO2001032690A1 Substituted dipeptides having nos inhibiting activity |
| 05/10/2001 | WO2001032687A1 10 human secreted proteins |
| 05/10/2001 | WO2001032685A2 Gene expression directed by a super-psa promoter |
| 05/10/2001 | WO2001032683A1 Production of polymorphic forms i and ii of finasteride by complexation with group i or ii metal salts |
| 05/10/2001 | WO2001032680A2 18-nor-steroids as selectively active estrogens |
| 05/10/2001 | WO2001032677A1 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 05/10/2001 | WO2001032675A1 32 human secreted proteins |
| 05/10/2001 | WO2001032663A2 Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same |